Tiziana Life Sciences (TLSA) Receivables - Other (2017 - 2025)

Tiziana Life Sciences (TLSA) has reported Receivables - Other for 9 consecutive years, with $4.0 million the latest figure, recorded in Q4 2025.

• Quarterly Receivables - Other rose 10.45% year-over-year to $4.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $4.0 million (up 10.45% YoY) and the FY2025 annual result came in at $4.0 million, up 10.45% from the prior year.
• Receivables - Other fell to $4.0 million in Q4 2025 per TLSA's latest filing, from $4.9 million in the prior quarter.
• Over the last five years, Receivables - Other for TLSA reached as high as $4.9 million in Q2 2025 and fell as low as $456000.0 in Q4 2021.
• A 5-year average of $2.9 million and a median of $3.6 million in 2023 frame the typical range for Receivables - Other.
• Annual changes were most pronounced in 2022 — Receivables - Other soared 896.93% — and 2024, when it fell 21.85%.
• Year by year, Receivables - Other stood at $456000.0 in 2021, then surged by 896.93% to $4.5 million in 2022, then decreased by 11.66% to $4.0 million in 2023, then declined by 10.18% to $3.6 million in 2024, then advanced by 10.45% to $4.0 million in 2025.
• According to Business Quant data, Receivables - Other over the past three periods registered $4.0 million, $4.9 million, and $3.6 million for Q4 2025, Q2 2025, and Q4 2024 respectively.